Developer docs
API playgroundTry for free, no card

Search company profiles

C4 Therapeutics

Full company profile

uuid0000mef

Namestring
C4 Therapeutics
Legal namestring
C4 Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company founded in December 2015 and headquartered in Watertown, Massachusetts, that develops orally bioavailable small-molecule drugs based on targeted protein degradation (TPD). Its central technology is the proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform, which combines computational and experimental methods to design two complementary degrader classes: MonoDAC molecular glue degraders (binding E3 ligases such as Cereblon to create new target surfaces) and BiDAC heterobifunctional degraders (one end binding the disease target, the other binding the E3 ligase), supported by a Cereblon Toolkit of E3-ligase-binding ligands. The company's lead clinical assets are cemsidomide (CFT7455), an IKZF1/3 MonoDAC degrader for relapsed/refractory multiple myeloma that showed a 53% overall response rate at the recommended Phase 2 dose in 73 heavily pretreated patients, and CFT8919, an allosteric BiDAC degrader selective for EGFR L858R-mutant NSCLC that retains activity against resistance mutations such as L858R-C797S. Additional earlier-stage programs target BRAF V600X solid tumors (CFT1946) and BRD9 in synovial sarcoma/SMARCB1-null tumors (CFT8634), and the company has begun expanding into degrader-antibody conjugates (DACs) as a new modality.

Because C4T has no approved or commercialized products, its revenue model is built on strategic partnerships that provide upfront payments, development and regulatory milestone receipts, and tiered royalties on net sales. Active partners include Roche (initial collaboration since January 2016, expanded in April 2026 with $20M upfront and over $1B in potential milestones for DACs), Biogen (since December 2018, advancing TORPEDO-derived candidates), Betta Pharmaceuticals (May 2023 exclusive license for CFT8919 in Greater China, up to $357M in milestones plus royalties), and Merck KGaA (February 2024 collaboration on KRAS degraders), with Pfizer added in October 2025 for a cemsidomide-elranatamab combination trial. The company goes to market through enterprise-style pharma licensing and co-development rather than a traditional salesforce, and supports this with scientific publications, presentations at oncology conferences (EHA, ASH, ASCO, AACR, ESMO), and investor-focused communications. The company is publicly traded on NASDAQ with a market capitalization of approximately $261-265M as of February 2026, a cash burn of approximately $96M annually, and an October 2025 $125M underwritten offering (with up to $349.7M including warrant exercise) that extends its cash runway through 2028.

Short descriptiontext

C4 Therapeutics is a clinical-stage biopharmaceutical company that designs orally bioavailable targeted protein degrader medicines via its TORPEDO platform, advancing lead candidates cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC while licensing programs to large-pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, oncology drug development, protein degrader therapeutics, molecular glue degraders, heterobifunctional degraders
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Targeted Protein Degradation Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Licensing Revenue
TypeLicensing Royalties
Description

C4 Therapeutics generates revenue through strategic partnerships with pharmaceutical companies. The company receives upfront payments, milestone payments tied to development and regulatory achievements, and royalties on net sales of approved products. Key partnerships include Roche (DACs), Biogen (TORPEDO platform), Betta Pharmaceuticals (CFT8919 in Greater China), and Merck KGaA (KRAS programs).

biospace.com
2Equity Financing
TypeSubscription Recurring
Description

The company has raised capital through underwritten equity offerings, including a $125 million offering in October 2025 with potential up to $349.7 million if all warrants are exercised. This extends the company's cash runway to 2028.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

C4 Therapeutics discovers and develops orally bioavailable small-molecule drugs that use targeted protein degradation to eliminate disease-causing proteins, with two clinical-stage oncology candidates (Cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC). The company advances these candidates internally through clinical trials and through co-development/licensing partnerships with larger pharmaceutical companies that handle later-stage development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 53% overall response rate at 100µg recommended Phase 2 dose in 73 heavily pretreated relapsed/refractory multiple myeloma patients
+1 more record
Product overview1 text field

C4 Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of medicines through targeted protein degradation (TPD). The company's core offerings include the TORPEDO drug discovery platform, which enables development of MonoDAC molecular glue degraders and BiDAC heterobifunctional degraders. Clinical-stage candidates include Cemsidomide (IKZF1/3 degrader for multiple myeloma) and CFT8919 (EGFR L858R degrader for non-small cell lung cancer). The company also develops degrader-antibody conjugates (DACs) as an emerging modality, combining degraders with antibodies for enhanced tumor targeting. All investigational medicines are orally bioavailable small molecules.

Product and service4 records
1Cemsidomide (CFT7455)
CategoryClinical-stage drug candidate
2CFT8919
CategoryClinical-stage drug candidate
3TORPEDO Platform
CategoryDrug discovery platform
4Degrader-Antibody Conjugates (DACs)
CategoryEmerging therapeutic modality
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Roche and C4 Therapeutics have partnered since January 2016 to advance research in targeted protein degradation. The partnership was expanded in April 2026 to develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets with an option for a third. C4T receives $20 million upfront payment and is eligible for over $1 billion in discovery, development, and commercial milestones, plus tiered royalties on future sales. C4T uses TORPEDO platform for degrader payload design while Roche handles antibody selection, conjugation, and advances candidates through preclinical, clinical development, and commercialization.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Clinical trial collaboration signed in October 2025 for evaluation of cemsidomide in combination with elranatamab (ELREXFIO). Pfizer provides elranatamab at no cost while C4T sponsors and conducts the Phase 1b trial in relapsed/refractory multiple myeloma patients.

3Merck KGaA, Darmstadt, Germany
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

C4 Therapeutics and Merck KGaA announced a strategic discovery research collaboration in February 2024 against critical oncogenic proteins within the KRAS family. C4T utilizes its TORPEDO platform to discover degraders for treatment of KRAS-mutant cancers while Merck KGaA is responsible for clinical development and commercialization.

c4therapeutics.com
4Betta Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-30
Description

C4T and Betta Pharmaceuticals entered into an exclusive licensing agreement in May 2023 for development and commercialization of CFT8919 in Greater China (China, Hong Kong SAR, Macau SAR, Taiwan). C4T is eligible for up to $357 million in potential milestones plus royalties on net sales. Betta is responsible for development, manufacturing, and commercialization in licensed territories.

finanznachrichten.de
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

C4 Therapeutics and Biogen entered into a strategic collaboration in December 2018 to use C4T's TORPEDO platform to discover and develop potential new treatments. C4T provides expertise and research services in targeted protein degradation while Biogen provides scientific and drug development capabilities. Biogen advances candidates through clinical development and potential commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company pioneering targeted protein degradation via its PROTAC platform (heterobifunctional degraders). Most direct competitor to C4T in oncology and neuroscience, with overlapping degrader modality, similar platform-driven strategy, and comparable partnership-heavy business model.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule targeted protein degraders using its Pegasus platform across immunology and oncology indications. Directly comparable to C4T in modality (heterobifunctional and molecular glue degraders), pipeline stage, and partnership-driven model.

TypeDirect peer
Description

Clinical-stage biotech focused on molecular glue degraders for oncology and other diseases, with a discovery platform similar in approach to C4T's TORPEDO. Competes for the same degrader discovery talent, target space, and pharma partnership dollars.

TypeDirect peer
Description

Clinical-stage company developing medicines targeting chromatin biology, including protein degradation-based approaches to historically undruggable cancer targets. Comparable as a clinical-stage platform-driven oncology biotech with degrader-related modality.

TypeEmerging player
Description

Early-stage company developing targeted protein degraders for oncology and other diseases, including STING-related and other targets. Less capitalized and earlier-stage than C4T but operates in the same TPD modality and oncology focus.

TypeEmerging player
Description

Clinical-stage company developing targeted protein degraders (molecular glues and heterobifunctionals) for hematologic malignancies and solid tumors. Similar degrader modality and oncology pipeline to C4T but at smaller scale and earlier stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors27 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

C4 Therapeutics

Targeted Protein Degradation Therapeuticsc4therapeutics.com

C4 Therapeutics is a clinical-stage biopharmaceutical company that designs orally bioavailable targeted protein degrader medicines via its TORPEDO platform, advancing lead candidates cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC while licensing programs to large-pharma partners.

What C4 Therapeutics does

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company founded in December 2015 and headquartered in Watertown, Massachusetts, that develops orally bioavailable small-molecule drugs based on targeted protein degradation (TPD). Its central technology is the proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform, which combines computational and experimental methods to design two complementary degrader classes: MonoDAC molecular glue degraders (binding E3 ligases such as Cereblon to create new target surfaces) and BiDAC heterobifunctional degraders (one end binding the disease target, the other binding the E3 ligase), supported by a Cereblon Toolkit of E3-ligase-binding ligands. The company's lead clinical assets are cemsidomide (CFT7455), an IKZF1/3 MonoDAC degrader for relapsed/refractory multiple myeloma that showed a 53% overall response rate at the recommended Phase 2 dose in 73 heavily pretreated patients, and CFT8919, an allosteric BiDAC degrader selective for EGFR L858R-mutant NSCLC that retains activity against resistance mutations such as L858R-C797S. Additional earlier-stage programs target BRAF V600X solid tumors (CFT1946) and BRD9 in synovial sarcoma/SMARCB1-null tumors (CFT8634), and the company has begun expanding into degrader-antibody conjugates (DACs) as a new modality.

Because C4T has no approved or commercialized products, its revenue model is built on strategic partnerships that provide upfront payments, development and regulatory milestone receipts, and tiered royalties on net sales. Active partners include Roche (initial collaboration since January 2016, expanded in April 2026 with $20M upfront and over $1B in potential milestones for DACs), Biogen (since December 2018, advancing TORPEDO-derived candidates), Betta Pharmaceuticals (May 2023 exclusive license for CFT8919 in Greater China, up to $357M in milestones plus royalties), and Merck KGaA (February 2024 collaboration on KRAS degraders), with Pfizer added in October 2025 for a cemsidomide-elranatamab combination trial. The company goes to market through enterprise-style pharma licensing and co-development rather than a traditional salesforce, and supports this with scientific publications, presentations at oncology conferences (EHA, ASH, ASCO, AACR, ESMO), and investor-focused communications. The company is publicly traded on NASDAQ with a market capitalization of approximately $261-265M as of February 2026, a cash burn of approximately $96M annually, and an October 2025 $125M underwritten offering (with up to $349.7M including warrant exercise) that extends its cash runway through 2028.

C4 Therapeutics firmographics

Firmographics
Name
C4 Therapeutics
Legal name
C4 Therapeutics, Inc.
Website
https://c4therapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
C4 Therapeutics is a clinical-stage biopharmaceutical company that designs orally bioavailable targeted protein degrader medicines via its TORPEDO platform, advancing lead candidates cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC while licensing programs to large-pharma partners.
Ownership category
akta.pro rank

C4 Therapeutics industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Oncology drug development
  • Protein degrader therapeutics
  • Molecular glue degraders
  • Heterobifunctional degraders

Where C4 Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

C4 Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and Licensing Revenue: C4 Therapeutics generates revenue through strategic partnerships with pharmaceutical companies. The company receives upfront payments, milestone payments tied to development and regulatory achievements, and royalties on net sales of approved products. Key partnerships include Roche (DACs), Biogen (TORPEDO platform), Betta Pharmaceuticals (CFT8919 in Greater China), and Merck KGaA (KRAS programs).
  2. Equity Financing: The company has raised capital through underwritten equity offerings, including a $125 million offering in October 2025 with potential up to $349.7 million if all warrants are exercised. This extends the company's cash runway to 2028.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

C4 Therapeutics product offering

Product offering

Core offering

C4 Therapeutics discovers and develops orally bioavailable small-molecule drugs that use targeted protein degradation to eliminate disease-causing proteins, with two clinical-stage oncology candidates (Cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC). The company advances these candidates internally through clinical trials and through co-development/licensing partnerships with larger pharmaceutical companies that handle later-stage development and commercialization.

Product overview

C4 Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of medicines through targeted protein degradation (TPD). The company's core offerings include the TORPEDO drug discovery platform, which enables development of MonoDAC molecular glue degraders and BiDAC heterobifunctional degraders. Clinical-stage candidates include Cemsidomide (IKZF1/3 degrader for multiple myeloma) and CFT8919 (EGFR L858R degrader for non-small cell lung cancer). The company also develops degrader-antibody conjugates (DACs) as an emerging modality, combining degraders with antibodies for enhanced tumor targeting. All investigational medicines are orally bioavailable small molecules.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cemsidomide (CFT7455)
  • CFT8919
  • TORPEDO Platform
  • Degrader-Antibody Conjugates (DACs)

Quantifiable outcome

  • 53% overall response rate at 100µg recommended Phase 2 dose in 73 heavily pretreated relapsed/refractory multiple myeloma patients
  • +1 more outcomes

Companies that use C4 Therapeutics

Customer profile

Segments4 records

Ideal customer profiles1 record

C4 Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

C4 Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, minor and core.

  • RocheflagshipStrategic or Co-development Partner · 9 April 2026Roche and C4 Therapeutics have partnered since January 2016 to advance research in targeted protein degradation. The partnership was expanded in April 2026 to develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets with an option for a third. C4T receives $20 million upfront payment and is eligible for over $1 billion in discovery, development, and commercial milestones, plus tiered royalties on future sales. C4T uses TORPEDO platform for degrader payload design while Roche handles antibody selection, conjugation, and advances candidates through preclinical, clinical development, and commercialization.
  • PfizerminorStrategic or Co-development Partner · 1 October 2025Clinical trial collaboration signed in October 2025 for evaluation of cemsidomide in combination with elranatamab (ELREXFIO). Pfizer provides elranatamab at no cost while C4T sponsors and conducts the Phase 1b trial in relapsed/refractory multiple myeloma patients.
  • Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 1 February 2024C4 Therapeutics and Merck KGaA announced a strategic discovery research collaboration in February 2024 against critical oncogenic proteins within the KRAS family. C4T utilizes its TORPEDO platform to discover degraders for treatment of KRAS-mutant cancers while Merck KGaA is responsible for clinical development and commercialization.
  • Betta PharmaceuticalscoreStrategic or Co-development Partner · 30 May 2023C4T and Betta Pharmaceuticals entered into an exclusive licensing agreement in May 2023 for development and commercialization of CFT8919 in Greater China (China, Hong Kong SAR, Macau SAR, Taiwan). C4T is eligible for up to $357 million in potential milestones plus royalties on net sales. Betta is responsible for development, manufacturing, and commercialization in licensed territories.
  • BiogencoreStrategic or Co-development Partner · 1 December 2018C4 Therapeutics and Biogen entered into a strategic collaboration in December 2018 to use C4T's TORPEDO platform to discover and develop potential new treatments. C4T provides expertise and research services in targeted protein degradation while Biogen provides scientific and drug development capabilities. Biogen advances candidates through clinical development and potential commercialization.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

C4 Therapeutics competitors and assessment

Company assessment

Peers

Direct peers

  • Arvinas: Clinical-stage biopharmaceutical company pioneering targeted protein degradation via its PROTAC platform (heterobifunctional degraders). Most direct competitor to C4T in oncology and neuroscience, with overlapping degrader modality, similar platform-driven strategy, and comparable partnership-heavy business model.
  • Kymera Therapeutics: Clinical-stage biotech developing small molecule targeted protein degraders using its Pegasus platform across immunology and oncology indications. Directly comparable to C4T in modality (heterobifunctional and molecular glue degraders), pipeline stage, and partnership-driven model.
  • Monte Rosa Therapeutics: Clinical-stage biotech focused on molecular glue degraders for oncology and other diseases, with a discovery platform similar in approach to C4T's TORPEDO. Competes for the same degrader discovery talent, target space, and pharma partnership dollars.
  • Foghorn Therapeutics: Clinical-stage company developing medicines targeting chromatin biology, including protein degradation-based approaches to historically undruggable cancer targets. Comparable as a clinical-stage platform-driven oncology biotech with degrader-related modality.

Emerging players

  • Dialectic Therapeutics: Early-stage company developing targeted protein degraders for oncology and other diseases, including STING-related and other targets. Less capitalized and earlier-stage than C4T but operates in the same TPD modality and oncology focus.
  • BioTheryX: Clinical-stage company developing targeted protein degraders (molecular glues and heterobifunctionals) for hematologic malignancies and solid tumors. Similar degrader modality and oncology pipeline to C4T but at smaller scale and earlier stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

C4 Therapeutics social profiles

Digital presence

C4 Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

C4 Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

C4 Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

C4 Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C4 Therapeutics

What does C4 Therapeutics do?

C4 Therapeutics discovers and develops orally bioavailable small-molecule drugs that use targeted protein degradation to eliminate disease-causing proteins, with two clinical-stage oncology candidates (Cemsidomide for multiple myeloma and CFT8919 for EGFR-mutant NSCLC). The company advances these candidates internally through clinical trials and through co-development/licensing partnerships with larger pharmaceutical companies that handle later-stage development and commercialization.

Is C4 Therapeutics a public or private company?

C4 Therapeutics is a public company. It is classified as public and is currently operating.

When was C4 Therapeutics founded?

C4 Therapeutics was founded in 2015. It employs 101 to 250 people.

Where is C4 Therapeutics based?

C4 Therapeutics is headquartered in Watertown, United States, in the North America region.

How does C4 Therapeutics make money?

Two revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are equity Financing.

Who are C4 Therapeutics's main competitors?

Pfizer is listed as a peer. Direct peers are Arvinas, Kymera Therapeutics, Monte Rosa Therapeutics and Foghorn Therapeutics. Emerging players are Dialectic Therapeutics and BioTheryX.

Does C4 Therapeutics have an API?

No public API is recorded for C4 Therapeutics.

What industry is C4 Therapeutics in?

C4 Therapeutics's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comC4 Therapeutics at Jefferies Global Healthcare Conference: cemsidomide pushC4 Therapeutics presented cemsidomide data at Jefferies' healthcare conference, citing a 53% response rate in heavily pre-treated multiple myeloma patients. The company plans a late-line MOMENTUM study and a second-line combination with Pfizer's elranatamab, with cash runway through 2028.Quiver QuantitativeC4 Therapeutics Stock Short Interest Rises to 38.09% | CCCC Stock NewsC4 Therapeutics short interest rose to 38.09% of the float on October 30th, totaling 46.58 million shares, up 9.03% from October 15th. It would take 15.14 days to cover short positions at current volume. Hedge fund activity shows 94 institutions added shares while 62 reduced positions in the most recent quarter.American Banking and Market NewsCandriam S.C.A. Acquires 963,409 Shares of C4 Therapeutics, Inc. $CCCCCandriam S.C.A. increased its stake in C4 Therapeutics by 53.6% in Q3, buying 963,409 shares to hold 2,760,346 shares, representing about 2.24% of the company. Analysts have a consensus "Moderate Buy" rating with an average price target of $8.50.Simply Wall StC4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price TargetsC4 Therapeutics reported Q3 revenue of $8.5M, in line with expectations, but statutory losses per share of $0.16 were 18% smaller than expected. Analysts raised the consensus price target to $12.50, though forecasts imply a 31% revenue decline and losses of $0.92 per share for 2027.American Banking and Market NewsC4 Therapeutics (NASDAQ:CCCC) Rating Lowered to “Sell” at Wall Street ZenWall Street Zen downgraded C4 Therapeutics from 'hold' to 'sell' on Saturday. The stock opened at $3.10, with a consensus rating of 'Moderate Buy' and a target price of $8.50. Analysts expect a fiscal-year EPS of -$0.81.The future of tradingC4 Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryC4 Therapeutics reported a quarterly adjusted loss of 16 cents per share for the quarter ended September 30, beating the analyst mean of -20 cents. Revenue fell 24.6% to $8.47 million from a year ago, and the company posted a $2.18 million loss.YahooC4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue EstimatesC4 Therapeutics reported a Q3 loss of $0.16 per share, beating the consensus estimate of $0.20, but revenue of $8.47 million missed estimates by 5.17%. The company has surpassed consensus EPS estimates four times in the last four quarters. Management's commentary will influence near-term stock movement.Business & FinancialC4 Therapeutics To Participate In Upcoming November Investor ConferencesC4 Therapeutics management will participate in two investor conferences in November 2026: a fireside chat on November 9 in Boston and a presentation and fireside chat on November 17 in London. The live webcasts will be available on the company's website, with archived replays for about 90 days.Stock TitanC4 Therapeutics to join two investor conferences in Nov.C4 Therapeutics management will participate in two investor conferences in November 2026, one in Boston on November 9 and another in London on November 17. The company will host fireside chats and presentations, with webcasts available on its website.American Banking and Market NewsC4 Therapeutics, Inc. (CCCC) – What Are Investment Firms Thinking About This Stock?C4 Therapeutics received an average 'Moderate Buy' rating from five analysts, with a $9.33 price target. The company reported Q2 net loss of $0.18 per share, beating the consensus of $0.23, and revenue of $6.64 million versus $4.00 million expected. Analysts forecast a fiscal-year loss of $0.81 per share.